oricar-017
Cell therapyexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Oct 26, 2023 (NCT06182696)
Timeline
2020s
- Jan 1, 2023
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
- Blood Protein Disorders · Phase 1
- Cardiovascular Diseases · Phase 1
- Hematologic Diseases · Phase 1
- Hemorrhagic Disorders · Phase 1
- Hemostatic Disorders · Phase 1
- Immune System Diseases · Phase 1
- Immunoproliferative Disorders · Phase 1
- Lymphoproliferative Disorders · Phase 1
- Multiple Myeloma · Phase 1/Phase 2
- Neoplasms · Phase 1
- Neoplasms by Histologic Type · Phase 1
- Neoplasms, Plasma Cell · Phase 1
- Paraproteinemias · Phase 1
- Vascular Diseases · Phase 1
Mechanism of action
- Retinoic acid-induced protein 3Immunity, passive
GPRC5A immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06271252 | Phase 1 | Apr 3, 2024 | OriCell Therapeutics Co., Ltd. |
| NCT06182696 | Phase 1/Phase 2 (Phase 2) | Oct 26, 2023 | OriCell Therapeutics Co., Ltd. |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| OriCell Therapeutics Co., Ltd. | For profit | 2 | 2 | 2 | 2023 |
1 organizations
Page 1 / 1